Cancer Research
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of etigilimab and nivolumab, including in PD-L1 negative or low subjects Excerpt from the Press Release: LONDON and MOUNTAIN VIEW, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma…
Read More
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone Excerpt from the Press Release: LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 16, 2022 /PRNewswire/ — Marengo Therapeutics, a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today announced it is advancing its lead TCR activator, STAR0602, into the clinic following clearance of its…
Read More
– Clinicians agree that evidence supports testing benefits for all – Excerpt from the Press Release: SAN FRANCISCO, Sept. 15, 2022 /PRNewswire/ — Invitae ( NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology, underscoring the importance of universal germline testing for…
Read More
-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with both adenocarcinoma and squamous cell carcinoma- Excerpt from the Press Release: SAN CARLOS, Calif., Sept. 10, 2022 (GLOBE NEWSWIRE) — Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the…
Read More
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3 distinct and different KRAS mutations, confirming the MOA of rigosertib being KRAS+ agnostic 4 of 14 (29%) evaluable patients demonstrated disease control The combination…
Read More
HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Updated results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival (OS) benefit…
Read More
TumorGen’s microfluidic platform traps metastatic cancer cell clusters from lung cancer patients, creating new opportunities for anti-metastatic drug development. Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters (MCCCs) from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology.…
Read More
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor Xerna™ TME Panel biomarker subtype and treatment response Excerpt from the Press Release: WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company…
Read More
The goal is first-in-human use of NaNots™, injectable absorptive nanoparticles that treat cancer via clearance of tumor-generated immune inhibitors from blood. Excerpt from the Press Release: MILL VALLEY, Calif.–(BUSINESS WIRE)–NaNotics LLC, a biopharmaceutical company developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration…
Read More